{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:19:02Z","timestamp":1761488342252},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,11,9]],"date-time":"2009-11-09T00:00:00Z","timestamp":1257724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p><jats:bold>Abstract.\u2002<\/jats:bold> Stanley M (University of Cambridge, Cambridge, UK). Prophylactic HPV vaccines: will they do their job? (Foresight). <jats:italic>J Intern Med<\/jats:italic> 2010; <jats:bold>267<\/jats:bold>: 251\u2013259<\/jats:p><jats:p>The prophylactic HPV L1 virus like particle vaccines are highly efficacious preventing &gt;98% of HPV 16\/18 caused high grade cervical intra\u2010epithelial neoplasia (CIN2\/3) according to protocol group in phase III randomized clinical trials over approximately 4\u2003years. Data from the trials together with postvaccine surveillance indicates that they have a good safety profile. As the current HPV vaccines include only two of the 15 oncogenic HPVs, they will not eliminate cervical cancer or the other HPV associated ano\u2010genital diseases but could reduce, for example, the incidence of cervix cancer by up to 70\u201380%, if effectively delivered to adolescent females.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2009.02193.x","type":"journal-article","created":{"date-parts":[[2009,11,9]],"date-time":"2009-11-09T10:14:41Z","timestamp":1257761681000},"page":"251-259","source":"Crossref","is-referenced-by-count":15,"title":["Prophylactic human papillomavirus vaccines: will they do their job?"],"prefix":"10.1111","volume":"267","author":[{"given":"M.","family":"Stanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2]]},"reference":[{"issue":"3","key":"e_1_2_6_2_2","first-page":"S3\u201035","article-title":"Chapter 4: burden and management of non\u2010cancerous HPV\u2010related conditions: HPV\u20106\/11 disease","volume":"24","author":"Lacey CJ","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLG.0b013e31816a7135"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.03.064"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.09.002"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.5.927"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<341::AID-IJC10>3.0.CO;2-E"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.65.2.219"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/exmp.1999.2298"},{"issue":"3","key":"e_1_2_6_10_2","first-page":"S3\u201099","article-title":"Chapter 11: HPV vaccines: commercial research & development","volume":"24","author":"Inglis S","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11553"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.6.3959-3963.1995"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.046"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061760"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60852-6"},{"key":"e_1_2_6_17_2","first-page":"194","volume-title":"Pathobiology","author":"Bell JA","year":"1994"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.04.068"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.069"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.073"},{"issue":"3","key":"e_1_2_6_22_2","first-page":"S3\u2010106","article-title":"Chapter 12: prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley M","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.049"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.005"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.059"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)80449-9"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/597307"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/597309"},{"issue":"3","key":"e_1_2_6_29_2","first-page":"S3\u2010122","article-title":"Chapter 14: HPV vaccine introduction in industrialized countries","volume":"24","author":"Wright TC","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000253970.29190.5a"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60691-7"},{"key":"e_1_2_6_32_2","first-page":"457","article-title":"Interim estimates of human papillomavirus vaccination coverage in the school\u2010based program in Australia","volume":"32","author":"Brotherton JM","year":"2008","journal-title":"Commun Dis Intell"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.067"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a769"},{"issue":"3","key":"e_1_2_6_35_2","first-page":"S3\u2010132","article-title":"Chapter 15: HPV vaccine use in the developing world","volume":"24","author":"Kane MA","year":"2006","journal-title":"Vaccine"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.003"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(07)60015-0"},{"key":"e_1_2_6_38_2","first-page":"371","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2007","volume":"32","author":"Lawrence G","year":"2008","journal-title":"Commun Dis Intell"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21731"},{"issue":"3","key":"e_1_2_6_40_2","first-page":"S3\u201011","article-title":"Chapter 2: the burden of HPV\u2010related cancers","volume":"24","author":"Parkin DM","year":"2006","journal-title":"Vaccine"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2009.02193.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2009.02193.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T04:42:12Z","timestamp":1698900132000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2009.02193.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2796.2009.02193.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02193.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}